Rheumatoid arthritis (RA)

^PrCIMZIA® (certolizumab pegol) in combination with methotreaxate (MTX) is indicated for:

• reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by X-ray, in adult patients with moderately to severely active rheumatoid arthritis (RA).

^PrCIMZIA® may be used alone for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who do not tolerate MTX.

Psoriatic Arthritis

^PrCIMZIA® alone or in combination with methotrexate (MTX) is indicated for:

• reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis (PsA) who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs).

Ankylosing Spondylitis (AS)

^PrCIMZIA® is indicated for:

• reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy.

Plaque Psoriasis (PsO)

^PrCIMZIA® is indicated for:

• The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.